Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.

Leah K CuddyAlia O AliaMiranda A SalvoSidhanth ChandraTom N GrammatopoulosCraig J JustmanPeter T LansburyJoseph R MazzulliRobert J Vassar

Published in: Molecular neurodegeneration (2022)

We show new data to suggest that LNK-754 promoted the axonal trafficking and function of endolysosomal compartments, which we hypothesize decreased axonal dystrophy, reduced BACE1 accumulation and inhibited amyloid deposition in 5XFAD mice. Our results agree with previous work identifying FTase as a therapeutic target for treating proteinopathies and could have important therapeutic implications in treating AD.

Keyphrases

spinal cord injury
high fat diet induced
early onset
optic nerve
electronic health record
big data
insulin resistance
wild type
type diabetes
peripheral nerve